{"id":"NCT00936741","sponsor":"Corcept Therapeutics","briefTitle":"An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome","officialTitle":"An Open Label Extension Study of the Efficacy and Safety of CORLUXÂ® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-07","primaryCompletion":"2012-09","completion":"2012-09","firstPosted":"2009-07-10","resultsPosted":"2014-04-02","lastUpdate":"2014-04-02"},"enrollment":30,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cushing's Syndrome"],"interventions":[{"type":"DRUG","name":"mifepristone","otherNames":["CORLUX"]}],"arms":[{"label":"Mifepristone","type":"EXPERIMENTAL"}],"summary":"Participants in study C-1073-400 (NCT00569582) will be invited to participate in this extension study to examine the long term safety of mifepristone in the treatment of the signs and symptoms of endogenous Cushing's syndrome. Total treatment duration may be up to 12 months or longer at the discretion of the Investigator.","primaryOutcome":{"measure":"Number of Participants With Adverse Events","timeFrame":"Up to three years.","effectByArm":[{"arm":"Open-label","deltaMin":30,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":12},"locations":{"siteCount":15,"countries":["United States"]},"refs":{"pmids":["26507877","25013998"],"seeAlso":["http://clinicaltrials.gov/ct2/show/NCT00569582"]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":30},"commonTop":["Nausea","Blood potassium decreased","Fatique","Headache","Endometrial hypertrophy"]}}